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The gene encoding a conjugated bile acid hydrolase (CBAH) from Clostridium perfringens 13 has been cloned
and expressed in Escherichia coli, and its nucleotide sequence has been determined. Nucleotide and predicted
amino acid sequence analyses indicated that the gene product is related to two previously characterized
amidases, a CBAH from Lactobacillus plantarum (40% identity) and a penicillin V amidase from Bacillus
sphaericus (34% identity). The product is apparently unrelated to a CBAH from C. perfringens for which
N-terminal sequence information was determined. The gene product was purified from recombinant E. coli and
used to raise antibody in rabbits. The presence of the protein in C. perfringens was then confirmed by
immunoblot analysis. The protein was shown to have a native molecular weight of 147,000 and a subunit
molecular weight of 36,100, indicating its probable existence as a tetramer. Disruption of the chromosomal C.
perfringens CBAH gene with a chloramphenicol resistance cartridge resulted in a mutant strain which retained
partial CBAH activity. Polyacrylamide gel electrophoresis followed by enzymatic activity staining and immu-
noblotting indicated that the mutant strain no longer expressed the cloned CBAH (CBAH-1) but did express
at least one additional CBAH (CBAH-2). CBAH-2 was immunologically distinct from CBAH-1, and its mobility
on native polyacrylamide gels was different from that of CBAH-1. Furthermore, comparisons of pH optima and
substrate specificities of CBAH activities from recombinant E. coli and wild-type and mutant C. perfringens
provided further evidence for the presence of multiple CBAH activities in C. perfringens.
Among the many compounds metabolized by the gastroin-
testinal microflora of mammals are the endogenously pro-
duced bile acids. These ‘‘biological detergents’’ are synthesized
in the liver from cholesterol and are typically secreted in the
form of amino acid conjugates, with an amide bond between
the bile acid carboxyl group and the amino group of either
glycine or taurine. Once in the intestine, the bile acids may be
converted to a number of metabolites by the intestinal micro-
flora. One of the more common reactions, the hydrolysis of the
amide linkage, is catalyzed by a class of microbial enzymes
referred to collectively as conjugated bile acid hydrolases
(CBAH). These enzymes are produced by a number of differ-
ent bacteria, including, but not limited to, members of the
genera Clostridium, Bacteroides, Lactobacillus, Enterococcus,
and Bifidobacterium (1, 5, 9, 10, 12–14, 17, 20, 23–26, 33, 42, 43,
45). Because the efficient enterohepatic recirculation of bile
acids is partially dependent on their recognition in the conju-
gated form by active transport sites in the terminal ileum (8,
36), bacterial CBAH may be viewed as being in competition
with these active transport sites. Binding of a conjugated bile
acid to an active transport site results in its return to the liver,
while hydrolysis by bacterial CBAH results in production of a
free bile acid which binds with a lower affinity to the transport
sites (36, 40) and thus may pass into the large intestine or
cecum, where further metabolism may occur. The most impor-
tant metabolic transformation which these free bile acids may
undergo is 7-dehydroxylation. This reaction results in the con-
version of cholic acid or chenodeoxycholic acid to deoxycholic
acid or lithocholic acid, respectively. These last two ‘‘second-
ary’’ bile acids are more hydrophobic than their parent bile
acids and have been implicated in a variety of cytotoxic phe-
nomena (3, 30, 34, 37). Because of the important role which
CBAH plays in these subsequent reactions, we are interested
in the enzymology and the regulation of CBAH activity.
A CBAH from Clostridium perfringens is available commer-
cially and has been widely used for hydrolysis of conjugated of
bile acids preliminary to chemical analysis. Although a CBAH
from C. perfringensMCV 815 has been purified and character-
ized (11), little is known about the enzymology of the reaction
or the role the enzyme plays in the growth of the organism in
the gastrointestinal tract. The early studies of Nair and cowork-
ers (27–29, 35) suggested that there were actually multiple
forms of CBAH present in C. perfringens on the basis of ob-
servations of differential stabilities of activity against different
conjugated bile acids substrates. We present in this work a
confirmation of this earlier observation of multiple CBAHs in
C. perfringens and provide the nucleotide sequence and derived
amino acid sequence for one CBAH isozyme of C. perfringens
13.
MATERIALS AND METHODS
Bacterial strains, plasmids, and growth conditions. C. perfringens 13 was
obtained from Edmund Stellwag, Department of Biology, East Carolina Univer-
sity, and was grown on brain heart infusion medium (BHI) under an atmosphere
of CO2-H2-N2 (10:10:80) in a Coy anaerobic chamber at 378C. Escherichia coli
DH5aMCR and NM522 were obtained from GIBCO-BRL Life Technologies
and were grown aerobically on Luria-Bertani medium on a rotary shaker at 378C.
pUC18 (BamHI and bacterial alkaline phosphatase digested) and pKK233-2
were obtained from Pharmacia Biotech, Inc., and pHR106 (38) was obtained
from Phillip Hylemon, Medical College of Virginia, Virginia Commonwealth
University. The following compounds were added to growth media when appro-
priate at the indicated final concentrations: ampicillin, 100 mg/ml; chloramphen-
icol, 10 mg/ml; and isopropyl-b-D-thiogalactoside (IPTG), 0.2 mM.
Recombinant DNA techniques. Plasmid DNA was isolated from E. coli and C.
perfringens by the alkali lysis procedure (21). Templates for DNA sequencing
were purified with Qiagen columns (QIAGEN, Inc., Chatsworth, Calif.). Chro-
mosomal DNA was isolated from C. perfringens by the procedure of Marmur
(22), with the inclusion of the lysozyme pretreatment. Restriction endonuclease
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digestions were carried out as recommended by the suppliers. Electrophoresis of
DNA, ligation reactions, sucrose gradient centrifugation, and other nucleic acid
manipulations were performed as described by Maniatis et al. (21).
Plasmid library preparation. Genomic DNA from C. perfringens 13 was par-
tially digested and subjected to sucrose density gradient centrifugation as de-
scribed by Maniatis et al. (21). Fractions containing DNA in the 7-kb size range
were pooled, and an aliquot was ligated to BamHI-digested bacterial alkaline
phosphatase-treated pUC18 and transformed into E. coli DH5aMCR (Library
Efficiency; GIBCO-BRL). Following a 1-h outgrowth period, the cells were
spread onto plates containing the differential medium described by Christiaens et
al. (6). This medium is a modified Luria-Bertani agar containing additional
glucose as well as 0.5% sodium taurodeoxycholate and is buffered to pH 6.0.
Action of CBAH in this environment causes hydrolysis of the soluble sodium
taurodeoxycholate to deoxycholate, which is insoluble at the medium pH and
forms a white precipitate. After 12 to 24 h, plates were observed for colonies with
precipitated deoxycholate halos. These were picked and restreaked to purity.
DNA sequencing. DNA was sequenced by the dideoxynucleotide chain-termi-
nating method (39) with alkali-denatured double-stranded plasmid templates,
according to the procedure supplied with the Sequenase version 2.0 sequencing
reagent kit (U.S. Biochemical). Labeling reactions were performed with
[a-35S]ATP (1325 Ci/mmol; New England Nuclear). Universal M13/pUC for-
ward and reverse primers were used for sequencing those regions flanking vector
sequences, while internal regions were sequenced with specific primers based on
observed DNA sequences. All primers were synthesized by the DNA Synthesis
Core Laboratory, School of Medicine, East Carolina University.
Analysis of sequence data. Nucleic acid and protein sequence analyses were
performed with the GCG Sequence Analysis Software Package (Genetics Com-
puter Group, Inc., Madison, Wis.). Sequence information was submitted to
GenBank using AUTHORIN (Intelligenetics, Inc., Mountain View, Calif.).
Disruption of CBAH gene in C. perfringens. The clostridial chloramphenicol
acetyltransferase (CAT) gene contained on plasmid pHR106 (38) was excised by
digestion with EcoRI andHindIII. After the ends were blunted by treatment with
Klenow fragment, the CAT gene was ligated to a derivative of the original
CBAH-pUC18 recombinant plasmid. This derivative was generated by exonu-
clease III deletion of the upstream sequence to within 68 bp of the translational
start site, followed by digestion with XbaI and SmaI. The resulting CBAH-CAT
construct consisted of 679 bp of the N-terminal portion of the CBAH reading
frame (approximately two-thirds of the total), followed by the CAT gene, fol-
lowed by vector sequence. Since the pUC replicon is not active in C. perfringens
13, this construct was designed to disrupt the C. perfringens CBAH gene via
chromosomal recombination. The plasmid was introduced into C. perfringens by
electroporation. Cells were prepared by growing them anaerobically in BHI to
the mid-logarithmic phase of growth. After the cells had been harvested by
centrifugation at 6,0003 g for 15 min, they were washed twice in ice-cold 2.5 mM
sodium phosphate–10% (vol/vol) polyethylene glycol (pH 6.5) and resuspended
in 0.023 the original culture volume of this same buffer. Cell suspensions (120
ml) containing 1 to 5 mg of plasmid were electroporated at 5,000 V/cm with a
Bio-Rad Gene Pulser with Pulse Controller (0.2-cm cuvettes, 1,000 V, 25 mF,
infinite resistance setting). They were then immediately transferred to 5 ml of
BHI and incubated anaerobically at 378C for 3 h before aliquots were plated on
BHI agar plates containing 10 mg of chloramphenicol per ml. Chloramphenicol-
resistant colonies were restreaked to purity before large-scale liquid cultures
were grown. These cultures were used for protein and enzyme analysis, as well as
for DNA analysis to verify the presence of the CAT gene and altered CBAH
gene by restriction enzyme digestion and Southern blot analysis.
Protein and enzyme assays. Protein was assayed by the dye-binding method of
Bradford (4) with bovine serum albumin as the standard with commercially
available reagents (Bio-Rad Laboratories). Conjugated bile acid hydrolase ac-
tivity was assayed colorimetrically by measuring the amount of taurine liberated
after a fixed period at 378C. The standard assay was performed in 1.5-ml micro-
centrifuge tubes; the assay mixture contained, in a final volume of 0.5 ml, 25
mmol of sodium acetate (pH 5.5), 0.5 mmol of dithiothreitol, 0.5 mmol of EDTA,
1 mmol of sodium taurocholate, and enzyme. Reactions were initiated by the
addition of the sodium taurocholate after a 5-min equilibration at 378C. After 5
min, the reaction was stopped by addition of an equal volume of 20% (wt/vol)
trichloroacetic acid. After centrifugation for 5 min to remove precipitated pro-
tein, 100 ml of the mixture was assayed for free amino groups by the ninhydrin
reaction, using the procedure described by Lee and Takahashi (16). One unit of
activity is defined as that amount which catalyzes the liberation of 1 mmol of
taurine in 1 min under the conditions described above. To determine the effect
of buffer pH on enzymatic activity while avoiding the possibility of buffer-specific
reaction differences, a mixed-buffer system was used. A stock 23 buffer which
contained 30 mM citric acid, 30 mM boric acid, and 30 mMmonobasic potassium
phosphate was prepared. The pH of the buffer was adjusted to various points
from 2.5 to 9.0 in 0.5 pH unit increments with sodium hydroxide. Each of these
buffer stocks was used in place of the sodium acetate component in the standard
assay described above. The CBAH activity in chromatography fractions during
purification was monitored by a precipitation assay. Assays were performed in
round-bottom 96-well microtiter plates. Aliquots (1 to 20 ml) of fractions were
added to individual wells containing 100 ml of reaction cocktail (50 mM sodium
phosphate [pH 6.0], 10 mM 2-mercaptoethanol, 1 mM EDTA, 10 mM sodium
taurodeoxycholate). Samples containing CBAH activity generate free deoxy-
cholate, which is insoluble at the reaction pH. This is easily visualized as a white
precipitate after approximately 15 min in samples with high activity. The length
of time required to form visible precipitate corresponds roughly to the level of
activity in the fraction. By scoring plates for activity every 5 min, the relative
activity present in different fractions can be estimated very accurately.
Preparation of C. perfringens and E. coli cell extracts and purification of CBAH
from E. coli. All steps were performed at 48C, except for column chromatogra-
phies, which were performed at 258C. E. coli NM522 containing plasmid with the
CBAH gene downstream from the trp-lac promoter (see Results) was grown
from a 5% inoculum with overnight cultures in Luria-Bertani medium containing
100 mg of ampicillin per ml and 0.2 mM IPTG. Cells were harvested in the early
stationary phase of growth (approximately 7 h after inoculation) by centrifuga-
tion and resuspended in 3 volumes of 20 mM sodium phosphate–10 mM 2-mer-
captoethanol–1 mM EDTA (pH 7.0) (buffer A). The suspension was lysed by two
passages through a French pressure cell (14,000 lb/in2) and centrifuged at 17,000
3 g for 45 min to remove debris and unbroken cells. The supernatant was
adjusted to a protein concentration of approximately 20 mg/ml, brought to 50%
saturation with solid ammonium sulfate, equilibrated for 30 min at 48C, and then
centrifuged at 14,000 3 g for 30 min. The pellet was suspended in 0.53 the
original volume in buffer A containing 0.5 M ammonium sulfate (pH 6.0) (buffer
P). Following centrifugation at 5,000 3 g for 15 min to remove insoluble mate-
rial, the solution was applied to a phenyl-Sepharose CL-4B column (2.5 by 9.0
cm) equilibrated with buffer P. After the column was washed with buffer P until
the effluent A280 returned to baseline, CBAH was eluted with a linear decreasing
salt gradient (0.6 to 0 M ammonium sulfate in 20 mM sodium phosphate–10 mM
2-mercaptoethanol [pH 7.0]). Active fractions (as assayed by the 96-well plate
precipitation method) were combined and applied to a Q Sepharose Fast Flow
column equilibrated with 20 mM sodium phosphate–10 mM 2-mercaptoetha-
nol–5% glycerol (pH 7.0) (buffer Q). After the column was washed with buffer Q
until the effluent A280 had returned to baseline, CBAH was eluted with a 0 to 0.5
M NaCl gradient in buffer Q (200 ml total volume). Active fractions were
combined, concentrated by ultrafiltration through an Amicon YM-10 membrane,
and stored at2208C. Extracts from C. perfringens 13 (wild type and mutant) were
prepared by growing cells in BHI to either mid-logarithmic phase or late sta-
tionary phase. The harvested cell pellets were suspended in 3 volumes of buffer
A and disrupted by two passages through a French pressure cell. Following
centrifugation at 17,000 3 g for 45 min, the supernatant was dialyzed overnight
against buffer A and used without further purification for enzyme assays and
polyacrylamide gel electrophoresis (PAGE) analyses.
Production of antibody. Antibodies to CBAH were produced in the laboratory
of Mason Smith, School of Medicine, East Carolina University. CBAH purified
from E. coli was used to raise antibody in a female New Zealand White rabbit.
Following an initial injection in Freund’s complete adjuvant, booster injections
were given in Freund’s incomplete adjuvant. Serum from test bleeds was assayed
by Western blot (immunoblot) analysis to determine reactivity and specificity.
Following final bleeding by cardiac puncture, serum was allowed to clot at room
temperature for 2 h and centrifuged. The supernatant was stored overnight at
48C and recentrifuged to remove additional precipitate. Immunoglobulins were
then enriched by ammonium sulfate precipitation as described by Ausubel et al.
(2). Nonspecific antibodies to E. coli proteins were removed by treatment of
aliquots of the antibody solution with crude extracts prepared from E. coli
NM522 coupled to Sepharose (Affi-Gel 15; Bio-Rad), as described by Maniatis
et al. (21). Coupling of protein to the Affi-Gel was performed as specified by the
manufacturer.
Protein electrophoresis and immunoblotting. Sodium dodecyl sulfate (SDS)-
PAGE was carried out in 0.75-mm-thick gradient gels (7 to 20% total acrylamide
[T], 2.7% cross-linker [C]), using the discontinuous buffer system of Laemmli
(15). High- and low-molecular-weight protein standards (Bio-Rad Laboratories)
or 10-kDa molecular mass markers (GIBCO-BRL) were used as size markers.
Following electrophoresis, proteins were stained with 0.03% (wt/vol) Coomassie
brilliant blue R-250 in 15% (vol/vol) methanol–10% (vol/vol) acetic acid. Native
gel electrophoresis was carried out in 1.5-mm gradient gels (5 to 15% T, 2.7% C)
with the Laemmli buffer system, omitting the SDS and including 5 mM sodium
thioglycolate. Electrophoresis was conducted at 48C at 150 V (constant voltage)
until the bromphenol blue tracking dye reached the bottom of the gel. CBAH
activity was detected by first washing the gel twice for 15 min each in 250 ml of
0.5 M sodium acetate–10 mM 2-mercaptoethanol–1 mM EDTA (pH 5.5) at 108C
and then incubating the gel at 378C in 50 ml of 0.5 M sodium phosphate (pH
5.5)–10 mM 2-mercaptoethanol–10 mM sodium taurodeoxycholate. Within 1 h,
CBAH activity in the gel resulted in the formation of a white precipitate of
deoxycholic acid at the position of the enzyme. The gels were then photographed
under tungsten light on a glossy black background with Polaroid Type 55 film.
The negative was then rephotographed to produce the negative image shown in
this work. Control gels were incubated with the reaction buffer lacking taurode-
oxycholate to ensure that observed bands were not due to acid denaturation and
precipitation of proteins. For Western analyses, proteins were electrotransferred
to nitrocellulose membranes immediately following electrophoresis. The meth-
anol-Tris-glycine transfer buffer of Towbin et al. (46) was used for both SDS-
containing and native gels; however, native gels were incubated at 378C for 30
min in Laemmli tank buffer containing 0.5% SDS prior to electrotransfer to
facilitate the migration of proteins from the gel. Following incubation with the
NM522 extract-absorbed antiserum to CBAH, membranes were incubated with
VOL. 61, 1995 C. PERFRINGENS CONJUGATED BILE ACID HYDROLASE 2515
horseradish peroxidase-conjugated goat anti-rabbit immunoglobulin G. Detec-
tion was then performed with 4-chloro-1-naphthol reagent.
Determination of native molecular weight. CBAH purified from recombinant
E. coli as described above was chromatographed on a Sephacryl S-200 column
(2.5 by 95 cm) equilibrated with 20 mM sodium phosphate (pH 7.0), 100 mM
sodium chloride, and 10 mM 2-mercaptoethanol. The peak fractions were iden-
tified by measuring enzymatic activity in the 96-well plate assay. The column was
calibrated with cytochrome c (12.4 kDa), carbonic anhydrase (29 kDa), bovine
serum albumin (66 kDa), yeast alcohol dehydrogenase (150 kDa), and sweet
potato b-amylase (200 kDa).
Nucleotide sequence accession number. The nucleotide sequence of the DNA
fragment containing the CBAH gene has been submitted to GenBank with the
accession number U20191.
RESULTS
Identification and subcloning of the CBAH gene. A genomic
library of C. perfringens 13 was constructed by ligation of strain
13 DNA which had been partially digested with MboI-to-
BamHI-digested, phosphatase-treated pUC18. Following
transformation into E. coli DH5aMCR and plating on differ-
ential medium (6), 1 colony from the approximately 3,000 total
screened produced a halo of precipitate. This colony was
streaked to purity, plasmid was isolated, and crude extracts
were prepared and subjected to enzymatic analysis. Plasmid
isolates were shown to contain a 5,000-bp insert in pUC18 and
were designated pLH-1. Enzymatic analyses of crude extracts
verified that the strain was catalyzing the hydrolysis of tauro-
deoxycholate. Restriction mapping and exonuclease III dele-
tion analyses were performed to localize the CBAH gene on
this fragment. The restriction map and relationship of various
subclones to the parent fragment are depicted in Fig. 1. Dele-
tions from the HindIII end of the multiple cloning region into
the insert retained CBAH activity down to an insert size of
approximately 1,900 bp. Two of these deletion plasmids, dif-
fering in length by 36 bp, were used for the majority of the
sequencing, mutagenesis, and E. coli expression studies and are
designated pLH-9 and pLH-10. Additional deletions extending
further into the insert were used for DNA sequencing pur-
poses.
Nucleotide and amino acid sequence analysis. The region of
pLH-9 proximal to the HindIII side of the pUC18 multiple
cloning region, as well as more extensive exonuclease III-de-
leted inserts, were subjected to chain-terminating nucleotide
sequence analysis of both strands (Fig. 2). The resulting 1,087
bp of sequence information revealed a 990-bp open reading
frame (bases 69 to 1058), with a coding potential for a 329-
residue polypeptide (37,185 Da). The base composition of the
open reading frame (27.5% G1C) is consistent with a clostrid-
ial origin. A potential Shine-Dalgarno sequence was found
with a spacing of 11 bases to the putative start codon. A protein
database search revealed that the hypothetical polypeptide
(CPE13-A) is related to a CBAH from Lactobacillus plantarum
(LPL; 39.8% identity) (6), as well as to the penicillin V ami-
dase from Bacillus sphaericus (BSPPVA; 34.2% identity) (31)
(Fig. 3). Also included in the sequence comparison are the
sequences of N-terminal peptides determined from the
CBAHs purified from C. perfringens MCV 815 (CPE815) (11)
and from Lactobacillus sp. strain 100-100 (LSP100-A) (18).
While the two Lactobacillus sequences had 13 identical amino
acids over a stretch of 25 residues at the N terminus, there was
little sequence homology between the CBAHs from the two C.
perfringens strains (three matches over 13 residues, including
the N-terminal methionine). Although no definitive conclu-
sions should be drawn from comparisons within such a small
region, this does suggest that there may be fundamental dif-
ferences between the two C. perfringens enzymes. Also indi-
cated in Fig. 3 are residues which are conserved throughout all
three of the proteins whose complete predicted sequence is
shown. Several highly conserved regions are notable. Protein
database searches with these short peptide sequences provided
no information pointing to additional relatives to this cluster.
Expression and purification of CBAH from E. coli. To con-
firm the existence of a protein corresponding to the cloned
CBAH in the parent organism, we used immunoblot analyses.
For this purpose, it was necessary to purify sufficient amounts
of protein from recombinant E. coli for antibody preparation.
Expression was maximized by subcloning the CBAH reading
frame, along with the Shine-Dalgarno sequence, into a position
downstream from the trp-lac promoter of the expression vector
pKK223-3. This was facilitated by PCR amplification of the
cloned fragment with primers engineered to contain a BalI site
(59 end) and a HindIII site (39 end) (Fig. 2). After digestion of
the amplification reaction mixture with these two enzymes and
gel purification, the fragment was ligated to pKK223-3 pre-
pared by digestion with NcoI (promoter proximal) and filling in
protruding ends with Klenow fragment, followed by digestion
withHindIII (promoter distal). The resulting construct, pKLH-
101, when transformed into E. coli NM522, produced high
levels of CBAH activity in response to the presence of IPTG
(0.2 mM) in the growth medium. The enzyme from E. coli
NM522(pKLH-101) cultures induced with IPTG was purified
by a combination of ammonium sulfate fractionation, hydro-
phobic interaction chromatography (Phenyl Sepharose CL-4B),
and anion-exchange chromatography (Q Sepharose Fast Flow).
The results of a typical purification from 7 g (wet weight) of cells
(2 liters of culture) are summarized in Table 1. Approximately
200 to 300 mg of this material was used to raise rabbit antibody.
The remainder was used for physical and biochemical charac-
terization.
Native and subunit size of CBAH. Chromatography of pu-
rified CBAH-1 on a calibrated Sephacryl S-200 column pro-
vided a native molecular weight estimation of 147,000 (data
not shown). SDS-PAGE analysis of purified CBAH-1 indicated
a single polypeptide with molecular weight of 36,100. This
correlates well with the calculated molecular weight based on
analysis of the open reading frame (i.e., 37,185). Together,
these data suggest that the enzyme exists in its native state as
a tetramer.
Insertional mutagenesis of CBAH gene in C. perfringens 13.
The gene in C. perfringens corresponding to the cloned CBAH
gene was disrupted by insertional mutagenesis with a suicide
vector (pLH-CAT3) based on pUC8 and containing an N-
terminal portion of the CBAH gene upstream from the clos-
FIG. 1. Relationships between pLH-1 and derivatives. The originally cloned
fragments and four derivatives referred to in the text are shown. All members of
the pLH series are inserts in pUC-18, while pKLH-101 is derived from the
expression vector pKK233-2. The arrows above the CBAH and CAT genes
indicate the direction of transcription and translation. The arrow within the tac
promoter box indicates the orientation for transcript initiation. The downstream
terminator of pKK233-2 (T1T2) is indicated by the opposing arrows within the
boxed region. The bracket at the top of the figure indicates the region for which
the nucleotide sequence is reported in this work. This region was sequenced in
both strands over its entirety.
2516 COLEMAN AND HUDSON APPL. ENVIRON. MICROBIOL.
tridial CAT gene of pHR106 (Fig. 1). Thus, following electro-
poration of pLH-CAT3 into C. perfringens 13, the presence of
chloramphenicol-resistant colonies is indicative of recombina-
tion of the plasmid into the chromosome. This would most
probably be directed by the homology between the chromo-
somal CBAH gene and the fragment of the same gene present
on the plasmid. Southern blot analysis of DNA isolated from
several chloramphenicol-resistant colonies with a CBAH gene-
specific probe revealed a band shift relative to the wild-type
DNA, indicating that the recombinational event had taken
place within the CBAH gene (data not shown). One of these
mutants was chosen for enzymatic analyses and was designated
C. perfringens 13-3. It was grown in the presence of chloram-
phenicol at all times because of the potential instability of this
single-crossover type of insertional mutation.
CBAH expression in bacterial extracts. CBAH assays (nin-
hydrin method) were performed on extracts prepared from E.
coli NM522, DH5aMCR(pLH-1), and NM522(pKLH-101)
and C. perfringens 13 and 13-3. The results are shown in Table
2. Strain NM522(pKLH-101) (IPTG induced) expressed
CBAH at levels approximately 25-fold higher than did
DH5aMCR(pLH-1) and 180-fold higher than did C. perfrin-
gens 13. The putative insertional mutant, strain 13-3, continued
to express CBAH activity at 86% of wild-type levels. This result
suggested either that the CBAH-1 gene had not been inacti-
vated completely or that other CBAH enzymes were present,
with our enzyme, hereafter designated CBAH-1, making up
only a small fraction (14%) of the total CBAH activity.
SDS-PAGE fractionation followed by Western blot analysis
of crude extracts prepared from wild-type strain 13, mutant
FIG. 2. Nucleotide sequence of CBAH gene. The sequence represents the 59-proximal region of pLH-9. The 59 end of pLH-10 is at residue 37 (). The deduced
amino acid sequence is shown below the nucleotide sequence. A putative ribosome-binding region is underlined. The two oligonucleotide sequences used to amplify
the CBAH gene for overexpression in E. coli are shown at the 59 and 39 ends, along with the position of the BalI and HindIII sites contained within them. The sequence
of pUC18 which adjoins the 59 end of the CBAH gene in pLH-10 is shown between the CBAH gene and the 59 amplification primer. The XbaI cleavage site at residue
748 represents the 39 end of the CBAH derivative used for mutagenesis, after the introduction of the CAT gene between this position and the HindIII site of pUC18.
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strain 13-3, and E. coli NM522 with and without pKLH-101
indicated that CBAH-1 (37-kDa polypeptide) was present only
in wild-type strain 13 and in E. coli NM522 carrying the
CBAH-1 gene on the expression vector (Fig. 4A and B). No
immunoreactive bands corresponding to the position of
CBAH-1 were observed in C. perfringens 13-3 or E. coli NM522
lacking the CBAH gene, nor were new bands at different po-
sitions observed. The intensity of the CBAH-1 band in C.
perfringens 13 extracts did not change in log-phase versus sta-
tionary-phase cells, indicating that the protein was produced
constitutively throughout the growth cycle.
Native gel electrophoresis followed by CBAH activity stain-
ing clearly demonstrates the presence of an additional CBAH
(CBAH-2) in wild-type strain 13 and mutant strain 13-3 (Fig.
4C). Western blot analyses of parallel gels show that CBAH-2
is not immuno-cross-reactive with CBAH-1 (Fig. 4D). It should
be noted that the activities of CBAH-1 and CBAH-2 displayed
differential stabilities to the activity staining procedure. Thus,
the band intensity observed in Fig. 4C does not necessarily
reflect the amount of enzyme present and should be inter-
preted only qualitatively.
Substrate specificity of CBAHs. The dissimilarity of
CBAH-1 and CBAH-2 was apparent after substrate specificity
analyses (Table 2). This property is demonstrated best by an-
alyzing the T/G ratio, defined as the ratio of the hydrolysis rate
for taurocholic acid to that for glycocholic acid. CBAH-1 as-
says performed with crude protein extracts from recombinant
E. coli hydrolyzed taurocholate at a higher rate than glyco-
cholate (T/G ratio, 1.33), while extracts from wild-type strain
13, mutant strain 13-3, and the commercially available enzyme
preparation gave T/G ratios of 0.57, 0.32, and 0.38, respec-
tively. The higher T/G activity ratio of extracts containing the
cloned gene product relative to strain 13 extracts illustrates its
difference from the major CBAH activity of strain 13. The
lower ratio in the mutant strain 13-3 versus the wild type is
consistent with the loss of a CBAH activity with preference for
taurine-conjugated bile acids (CBAH-1) from a mixture of
CBAHs with overall preference for glycine conjugates.
pH optima for CBAH activities. Differences among the var-
ious extracts were also apparent with regard to pH-activity
profiles, and these are summarized in Table 2. The optimum
for activities of CBAH from extracts of strains 13 and 13-3, as
well as commercial cholylglycine hydrolase (Sigma), was pH
4.5. However, the activity expressed in extracts from E. coli
NM522(pKLH-101) had an optimum at pH 5.5.
DISCUSSION
The heterogeneity of CBAH among different genera of bac-
teria became apparent once the characterization of several of
these enzymes from different sources had been reported (11,
14, 28, 44). The major differences which have been observed
are in substrate specificity and molecular weight. The enzyme
from Bacteroides vulgatus was shown to preferentially hydro-
lyze taurine-conjugated bile acids (14), while those from two
Lactobacillus species (6, 18), C. perfringens (11, 28), and Bac-
teroides fragilis (44) were generally more active on glycine con-
jugates, with the degree of difference in hydrolysis rates varying
with the source organism as well as the bile acid moiety. In
addition, earlier studies by Mitvedt and Norman (25) with
bacterial cultures pointed to a diversity of enzymes. Some
FIG. 3. Amino acid sequence comparisons of the CBAH-PVA group. The
entire amino acid sequences (based on nucleotide sequence data) for the CBAH
from C. perfringens (CPE13-A; this work), the CBAH from L. plantarum (LPL)
(6), and the penicillin V amidase from Bacillus sphaericus (BSPPVA) (32) are
shown, along with the N-terminal sequences (italicized) of the CBAH from C.
perfringensMCV 815 (CPE815) (11) and the a polypeptide of the CBAH-A from
Lactobacillus sp. strain 100-100 (LSP100-A) (19). For the three entire sequences,
conserved amino acids are shown in capital letters. Shown below them is the
consensus sequence, with those residues identical in all three proteins indicated
in capital letters and those positions with conserved but nonidentical residues
indicated by the $. For the two N-terminal peptides, the capital letters designate
positions where there is identity with the protein from the related organism (i.e.,
CPE815 versus CPE13-A and LSP100-A versus LPL).
TABLE 1. Typical purification of cloned CBAH from E. coli
Purification step
Total
amt of
protein
(mg)
Total
activity
(U)a
Sp act
(U/mg)
Purifi-
cation
(fold)
Yield
(%)
Crude extract 251 96 0.38 1 100
0 to 50% ammonium
sulfate
142 86 0.61 1.6 90
Phenyl-Sepharose CL-
4B
23 50 2.17 5.7 52
Q Sepharose Fast Flow 0.9 29 32.22 84.8 30
a One unit is that amount of enzyme releasing 1 mmol of taurine per min under
the assay conditions described in Materials and Methods.
TABLE 2. Properties of CBAH activity from various extracts
Source Sp acta Relativeactivityb
T/G
ratioc
pH
optimum
C. perfringens 13 2.12 3 1023 1.00 0.52 4.5
C. perfringens 13-3 1.82 3 1023 0.86 0.32 4.5
E. coli NM522 NDd 0
E. coli DH5aMCR(pLH-1) 1.45 3 1022 6.84 NTe NT
E. coli NM522(pKLH-101) 3.80 3 1021 179 1.33 5.5
Cholylglycine hydrolase
(Sigma Chemical Co.)
NT 0.38 4.5
aMicromoles of taurine formed per minute per milligram of protein.
b Specific activity relative to that of C. perfringens 13.
c T/G ratio, activity on taurocholate/activity on glycocholate.
d ND, no activity detected.
e NT, not tested.
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organisms were capable of hydrolyzing both glycine and tau-
rine conjugates, while others preferred one or the other of the
two classes. These observations served as an indication that
there were a variety of CBAH enzymes in nature with distinct
substrate-hydrolyzing capabilities. It also was known, from
work by Nair and coworkers (27, 29, 35) and more recently by
Lundeen and Savage (19), that, even within a single strain of
bacteria, there was a heterogeneity with respect to CBAH
activities. C. perfringens ATCC 19574 was shown to produce
several enzymes with distinct but overlapping CBAH activities
against a variety of conjugated bile acid substrates. These en-
zymes also manifested differences with respect to one another
in thermal stability (35). Despite the commercial use of ex-
tracts from C. perfringens for their CBAH activity, no concerted
attempt has been made to purify and compare the individual
components of this apparent mixture of activities. In the case
of Lactobacillus sp. strain 100-100, at least four distinct CBAHs
have been observed, each composed of different combinations
of two separate polypeptides, a and b, in trimeric configuration
(19).
We have been interested in elucidating the role that this
group of enzymes plays in the gastrointestinal ecosystem and
had focused on C. perfringens 13 as the model organism. This
choice was based primarily on its utility for genetic studies
because of the relative ease with which it could be transformed
by electroporation (41). After being unsuccessful in attempts
to identify a CBAH gene from C. perfringens genomic libraries
with a DNA probe based on the N-terminal sequence of a
CBAH purified by Gopal-Srivastava and Hylemon (11), we
resorted to the indicator media method (7) used by Christiaens
et al. (6). We were promptly successful in cloning a gene which
encodes a protein product with CBAH activity. This gene and
its product, upon nucleotide sequence analysis and product
characterization, exhibited very little sequence or structural
similarity to the enzyme purified from C. perfringensMCV 815
(11). However, the product is related at the sequence level to
the previously described CBAH from L. plantarum (6), as well
as to the penicillin V amidase from Bacillus sphaericus (31, 32).
All three of these enzymes catalyze amide bond hydrolysis, all
have optimal activity at an acidic pH, and all are of similar size
(ca. 37-kDa subunits with probably tetrameric native compo-
sition). Protein and nucleic acid database searches with these
entire sequences or their highly conserved regions have not
revealed other obvious members of this family. Other than
inhibitor data suggesting the importance of a sulfhydryl group
to catalytic activity (11), nothing is known of the enzymatic
mechanism for any of these enzymes. Thus, it is difficult to even
speculate on the location of active-site residues.
FIG. 4. SDS-PAGE and native PAGE analyses of CBAHs. (A) Coomassie blue stain of proteins separated on SDS-PAGE gels (0.75 mm; total acrylamide [T], 10%;
cross-linker [C], 2.7%). Lanes: 1, 10-kDa marker; 2, NM522 (1 mg); 3, NM522(pKLH-101) (1 mg); 4, strain 13, log phase (50 mg); 5, strain 13, stationary phase (50 mg);
6, strain 13-3, log phase (50 mg); 7, strain 13-3, stationary phase (50 mg). (B) Western blot analysis of a gel identical to that in panel A, except that lane 1 contained
prestained markers. (C) Negative image of CBAH activity stain of proteins separated on nondenaturing polyacrylamide gels (1.5 mm; T, 7.5%; C, 2.7%). Lanes: 1,
NM522 (40 mg); 2, NM522(pKLH-101) (40 mg); 3, strain 13 (400 mg); 4, strain 13-3 (400 mg). (D) Western blot analysis of proteins separated as in panel C, except
that the gel was 0.75 mm thick. Lanes: 1, NM522 (4 mg); 2 and 3, NM522(pKLH-101) (lane 2, 2 mg; lane 3, 4 mg); 4 and 5, strain 13 (lane 4, 50 mg; lane 5, 100 mg);
6 and 7, strain 13-3 (lane 6, 50 mg; lane 7, 100 mg).
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The lack of homology of the CBAH gene from strain 13 with
that previously purified from C. perfringensMCV 815 led us to
examine strain 13 for additional CBAH activities. Using the
enzymatic activity assay after fractionation of extracts by
PAGE, we have shown that there is at least one additional
CBAH activity in crude extracts of strain 13. The failure of this
second activity to cross-react with antibody raised against
CBAH-1, along with the presence of this second activity in
mutant strains with a disrupted CBAH-1 gene, indicates that
this second enzyme is not a heteromultimer containing
CBAH-1 subunits, as was the case with the multiple forms of
CBAH observed in Lactobacillus sp. strain 100-100 (19). The
observation that the CBAH from C. perfringens MCV 815 had
a subunit size of 56 kDa (11), along with its N-terminal se-
quence dissimilarity, leads to the possibility that it is derived
from a different protein family from the penicillin amidase-
CBAH cluster. We are currently purifying and characterizing
the second CBAH (CBAH-2) from the strain 13 knockout
mutant to determine its relationship to CBAH-1.
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